Will IL28B polymorphism remain relevant in the era of direct‐acting antiviral agents for hepatitis C virus?

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|56|1|373-381

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.56, Iss.1, 2012-07, pp. : 373-381

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1365-1372

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. S1, 2018-02 ,pp. : 7-13

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reply to direct‐acting antiviral drugs and hepatitis C virus: A therapeutic revolution?

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4269-4270

John Wiley & Sons Inc

Access to resources Recommend Favorite

Direct‐acting antiviral drugs and hepatitis C virus: A therapeutic revolution?

By  

CANCER, Vol. 121, Iss. 23, 2015-12 ,pp. : 4268-4269

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acquired hemophilia A resolution in a hepatitis C virus/human immunodeficiency virus–coinfected patient with cure of hepatitis C by direct‐acting antiviral agents

By  

HEPATOLOGY, Vol. 67, Iss. 2, 2018-02 ,pp. : 794-796

John Wiley & Sons Inc

Access to resources Recommend Favorite